Microba Life Sciences Limited (AU:MAP) has released an update.
Microba Life Sciences Limited reported a significant revenue increase of 123.1% for the fiscal year ended June 30, 2024, with revenues reaching over $12 million. Despite this growth, the company’s net losses also increased by 57.2% to nearly $20 million, with no dividends paid out to shareholders. Additionally, the company expanded its market presence by acquiring UK-based Invivo Clinical Limited, a leader in microbiome testing.
For further insights into AU:MAP stock, check out TipRanks’ Stock Analysis page.
